Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)

2

Review clinical trials related to Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Selective Median Lobe Surgery Outcomes Study

This prospective multicenter observational cohort study will evaluate clinical outcomes after selective median lobe transurethral surgery for benign prostatic obstruction. Eligible men with lower urinary tract symptoms or urinary retention who are scheduled for selective median lobe-only TURP, HoLEP, or anatomical endoscopic enucleation as part of routine clinical care will be enrolled and followed after surgery. The study will collect preoperative clinical data, symptom scores, uroflowmetry, postvoid residual volume, prostate volume, intravesical prostatic protrusion measurements, cystoscopic anatomical findings, intraoperative variables, and postoperative outcomes. The primary outcome is composite clinical failure at 12 months. The main aim is to identify practical preoperative urology-based anatomical and functional predictors of clinical failure after selective median lobe surgery and to develop an exploratory prediction model that may help improve patient selection in future practice.

Participants needed: 420
Trial details
Age: 45+Biological sex: MaleType: ObservationalSponsor: Necmettin Erbakan UniversityUpdated: Jul 13, 2026Locations: 2
Eligibility criteria

Male patients aged 45 years or older. [+5]

Previous prostate surgery for benign prostatic hyperplasia. [+6]

Status: Not yet recruiting

Irreversible Electroporation (IRE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)

This study will evaluate the safety and effectiveness of using Irreversible Electroporation (IRE) for the treatment of symptomatic benign prostatic hyperplasia (BPH).

Participants needed: 40
Trial details
Age: 50+Biological sex: MaleType: InterventionalSponsor: Angiodynamics, Inc.Updated: Jun 11, 2026
Eligibility criteria

Male, age ≥50 years. [+8]

Patients with ≥ Grade Group 2 prostate cancer (≥ Gleason score 7). [+19]